The purpose of this study was to investigate the effects of combination therapy with methylprednisolone (MP) and Nogo-66 antagonistic peptide (NEP1-40) on morphological and functional recovery in adult rats subjected to thoracic compression spinal cord injury (SCI). Animals were randomized into four groups: a trauma control group, an MP group, an NEP1-40 group, and a combined treatment group. The inflammatory reaction, neuronal and oligodendrocyte survival, and ultrastructure were assessed at the injury site. Functional analysis was also performed using Basso, Beattie and Bresnahan (BBB) scoring. Rat behaviour was evaluated regularly up to week 4. NEP1-40 did not alter the beneficial effect of MP on haematogenous inflammatory cell infiltration, while combined treatment resulted in greater neuronal and oligodendrocyte survival compared with monotherapy or control. Combination therapy resulted in better locomotor scores. These results in a clinically-relevant SCI model showed that significant neuroprotection can be obtained by combining an initial acute IV injection of MP with continuously infused NEP1-40.
Introduction
Traumatic spinal cord injury (SCI) causes severe neurological damage and dysfunction in affected patients. The pathophysiology of acute SCI is characterized by an initial, mechanical injury (primary injury), followed by a series of secondary injurious events including ischaemia, calcium-and sodiummediated cellular injury, excitotoxic cell death, inflammation and apoptosis. 1 Pharmacological intervention in the acute phase of SCI aims to counteract secondary neurotoxic events or to interrupt the progression of this process. 2, 3 Over the last two decades, a large number of drugs, including steroids, gangliosides, ion channel blockers, anti-oxidants and free radical scavengers, have shown mild therapeutic effectiveness in experimental SCI. 4, 5 To date, only the administration of methyl -J Wu, H Yang, Z Qiu et al. Methylprednisolone and Nogo A monoclonal antibody in spinal cord injury prednisolone (MP) has been shown to be effective in humans, 3 -6 although its use has become controversial since data from some clinical trials failed to demonstrate conclusive beneficial outcomes. 5, 6 The proposed mechanisms of action of MP include anti-oxidant effects 3 and potent antiinflammatory effects mediated by suppression of nuclear factor κB binding. 7 Glucocorticoid receptor expression is rapidly but only transiently induced after SCI, 8 perhaps explaining the very limited therapeutic window of MP.
Another mechanism to promote functional recovery after SCI is through enhancing axonal regeneration. 9, 10 The adult mammalian central nervous system (CNS) has a limited capacity for nerve regeneration and structural plasticity. One of many explanations for the decreased amount of anatomical plasticity that occurs after adult CNS injury is the presence of myelin-associated inhibitory factors that block neurite outgrowth. 10, 11 Three molecules of CNS myelin have been identified as axon regeneration inhibitors: Nogo, myelinassociated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (OMgp). 12 All three purified proteins inhibit axon outgrowth from mature neurons in vitro. Remarkably, a single neuronal protein, the Nogo-66 receptor (NgR) binds all three proteins and appears to be the primary mediator of their action. 10, 13 The presence of myelin-derived inhibitors suggests that blocking their action might allow the intrinsic growth potential of CNS axons to be unmasked, with resultant functional recovery after adult CNS axotomy. Indeed, intrathecal application of an NgR competitive antagonist, the Nogo-66 antagonistic peptide (NEP1-40), produces significant axonal regrowth after SCI. 10, 14 Despite the promising effects exerted by MP and NEP1-40 after SCI, restoration of the function lost after injury is achieved only to a limited degree. 15 It is conceivable that a combination of strategies may bring about increased axonal growth and functional recovery. Thus, the present study was designed to investigate whether a combination of MP and NEP1-40 is superior to either treatment alone in a contusioninjury model in the rat spinal cord. The study investigated neurobehavioral and ultrastructural recovery and evaluated the biochemical responses to treatment of experimental SCI with low-dose intravenous MP, NEP1-40 continuous infusion, or a combination of both agents. The rationale for using this combination was based on the hypothesis that these treatments are complementary and are likely to be additive.
Materials and methods

ANIMALS
Female Wistar rats aged 12 weeks (250 -300 g) were used. The animals were obtained from the Experimental Animal Centre of Soochow University School of Medicine (Suzhou, China) and were housed in temperature-and humidity-controlled animal quarters with a 12-h light/dark cycle. All surgical interventions and post-operative animal care were carried out in accordance with the Guide for the Care and Use of Laboratory Animals 16 and approved by the Ethics Committee for Animal Experimentation of Soochow University.
SURGICAL PROCEDURES FOR THE SCI MODEL
All animals were anaesthetized with an intra-peritoneal (IP) injection of 10% chloral hydrate (400 mg/kg) and pinned in the prone position. Under sterile surgical conditions, following a midline skin incision at T5 -T12 and paravertebral muscle J Wu, H Yang, Z Qiu et al.
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dissection, the spinous processes and laminar arcs of T7 -T10 were removed with the assistance of a surgical microscope. The dura was left intact. As described previously, 17 weight-drop trauma was performed for all the animals. The SCI was performed at T8. After surgery, animals were placed in warmed cages to recover from anaesthesia. Manual bladder expression was performed twice a day for the duration of the study (4 weeks) or until return of function.
TREATMENT GROUPS
Four experimental groups were established in a randomized fashion: a trauma control group, a MP group, a NEP1-40 group, and a combined MP plus NEP1-40 treatment group. The trauma control group received an injection of 0.01 M phosphate-buffered saline (PBS), pH 7.2 -7.4, into the tail vein 30 min after injury. For MP treatment, rats received 60 mg/kg MP (Pfizer, New York, NY, USA) intravenously (IV) immediately after SCI and, 4 h later, they received a further 30 mg/kg MP IV. For NEP1-40 treatment, NEP1-40 (Beijing Biosynthesis Biotechnology Corp., Beijing, China) was dissolved in 0.01 M PBS, pH 7.2 -7.4, at a concentration of 0.33 mg/ml. An intrathecal catheter was inserted into the subarachnoid space at T8 and connected to a primed mini-osmotic pump inserted into the subcutaneous space. The mini-osmotic pump delivered NEP1-40 at a rate of 0.25 µl/h immediately after SCI. The osmotic pump was housed in a subcutaneous pocket in the back of the rat and was infused maximally for 4 weeks. MP and NEP1-40 at the same doses, administered by the same routes, were used in the combined treatment group.
IMMUNOHISTOCHEMICAL ANALYSIS
For immunohistochemical examination, animals were sacrificed at days 1 and 3, and week 4 after surgery by deep anaesthesia with an overdose of chloral hydrate (10%) and they were then transcardially perfused with 4% paraformaldehyde in 0.01 M PBS. A 5-mm cord segment containing the compression epicentre was dissected out, post-fixed for 2 h and then cryoprotected in 30% sucrose in 0.01 M PBS overnight at 4°C. The segments were then stored at -80°C in embedding compound. Coronal sections (30 µm) were cut using a freezing cryostat. The serial sections were stored in 0.01 M PBS at 4°C until examined. The inflammatory reaction was assessed at days 1 and 3, and neuronal and oligodendrocyte survival were assessed at week 4.
The general procedure for immunohistochemistry involved the frozen slides being air dried at room temperature for 30 min and washed with 0.01 M PBS for 10 min. They were then blocked with 1% bovine serum albumin, 10% normal goat serum and 0.3% Triton X-100 (Sigma-Aldrich, St Louis, MO, USA) in 0.01 M PBS for 1 h at room temperature. The following primary antibodies were then applied overnight at 4°C: rabbit anti-CD68 (ED1) polyclonal antibody (1:1000, Sigma-Aldrich); rabbit antineuronal nuclei antigen (NeuN) polyclonal antibody (1:1000, Sigma-Aldrich); and rabbit antimyelin basic protein (MBP) polyclonal antibody (1:1000, Sigma-Aldrich). On the following day, the slides were washed three times in 0.01 M PBS and incubated with fluorescein isothiocyanateconjugated goat antirabbit secondary antibody (1:100, Sigma-Aldrich) for 1 h at 37°C. Sections were then washed with 0.01 M PBS and incubated with the nucleusspecific counterstain 4,6-diamidino-2phenylindole dihydrochloride (DAPI, Sigma-Aldrich) to stain all cell nuclei. The images were captured using a Leica fluorescence microscope (LSM 510 META; Carl Zeiss, Methylprednisolone and Nogo A monoclonal antibody in spinal cord injury Oberkochen, Germany). The percentage of positively stained cells was measured by calculating the number of fluorescent cells within a microscope field as a percentage of the total number of cells within that same field.
ELECTRON MICROSCOPY TECHNIQUE
At week 4 post-injury, 1 mm of crosssectional grey and white matter at the epicentre of the spinal cord lesion was removed for ultrastructural examination. Tissue samples were prepared for electron microscopy by removing the spinal cord segments and fixing them in 2.5% glutaraldehyde for 24 h. Then the tissue was post-fixed with 1% osmium tetroxide, dehydrated in a graded series of alcohol and then embedded in 2-dodecenyl succinic anhydride (Araldite ® CY212, DDSA; Beijing Biosynthesis Biotechnology Corp., Beijing, China). Sections of 60 -90 nm were stained with uranyl acetate and lead citrate, examined on an electron microscope (JEM 1200EX;
Jeol, Tokyo, Japan) and photographed. During the observation, each sample was evaluated according to a quantitative grading system, which was established for different tissue samples and SCI by Gok et al (Table 1 ). 18
BEHAVIOURAL ASSESSMENT
Gross locomotor recovery after SCI was scored in an open field according to the Basso, Beattie and Bresnahan (BBB) locomotor rating scale of 0 (complete paralysis) to 21 (normal locomotion). 19 BBB scoring was performed at 1 and 3 days, and at 1, 2, 3 and 4 weeks post-injury. All behavioural tests were done in the morning between 09:00 and 12:00 h. Each rat was 
Results
IMMUNOHISTOCHEMICAL ANALYSES
Immunohistochemical analyses of spinal cord tissue after contusion injury were performed to compare the effects of the treatments on three variables: (i) macrophage and microglial recruitment; (ii) neuronal survival; and (iii) oligodendrocyte survival. To assess infiltration of the contusion site by haematogenous inflammatory cells, spinal cord tissue in the centre of the contusion was immunostained with ED1 antibody against CD68. During the early post-injury stage (days 1 and 3), ED1positive cells increased substantially. Fewer ED1-positive cells were seen at the contusion site in both the MP-only and combined treatment groups (Fig. 1B, 1D ) compared with the trauma control and NEP1-40-only treatment groups (Fig. 1A, 1C ). Quantitative analysis showed that these differences were statistically significant ( Fig. 1E ; P < 0.05). There were no significant differences between the MP-only treatment and combined treatment groups at days 1 or 3, although the proportion of ED1-positive cells in the MP-only treatment group was higher than it was in the combined treatment group.
To evaluate the survival of spinal cord motor neurons, NeuN immunoreactivity in the ventral horn was assessed at 4 weeks post-injury. The number of NeuN-positive cells increased in both the NEP1-40-only and combined treatment groups (Fig. 2C, 2D) , compared with the trauma control and MPonly treatment groups ( Fig. 2A, 2B ). Quantitative analysis showed that these differences were statistically significant ( Fig.  2E ; P < 0.05). There was also a significantly higher number of NeuN-positive cells in the combined treatment group compared with the NEP1-40-only treatment group ( Fig. 2E ; P < 0.01).
To identify the survival of spinal cord oligodendrocytes, MBP immunoreactivity was assessed at 4 weeks post-injury. Both the NEP1-40-only and combined treatment groups (Fig. 3C, 3D ) had increased numbers of MBP-labelled oligodendrocytes compared with the trauma control and MP-only treatment groups (Fig. 3A, 3B ). Quantitative analysis showed that these differences were statistically significant ( Fig. 3E ; P < 0.05). In the combined treatment group, there were significantly more MBP-labelled oligodendrocytes compared with the NEP1-40-only treatment group ( Fig. 3E ; P < 0.01).
ULTRASTRUCTURAL FINDINGS
Better preservation of the cytostructure was noted in the combined treatment group (Fig.  4D ) compared with all other groups (Fig. 4A -4C) at 4 weeks post-injury. The lamellar pattern and the density of the axoplasms were normal in appearance, and the volume of the axoplasms had increased (Fig. 4D) . The electron microscopy ultrastructural findings were quantitatively evaluated according to a previously published grading system (see Table 1 ) 18 4E . The combined treatment group showed significant differences in the number of small-, medium-and large-sized myelinated axons compared with the other three groups (P < 0.05). The grading scores for the mitochondria in neurons were also significantly different between the combined treatment group and the three other groups (P < 0.05). (E) Quantitative analysis at days 1 and 3 of the mean ± SD number of ED1-positive cells expressed as a percentage of the total number of cells within the microscope field showed that these differences were statistically significant (*P < 0.05 for B and D versus A and C)
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BEHAVIOURAL ASSESSMENT
The results of locomotor recovery after SCI, as measured by the BBB locomotor rating scale, are shown in Fig. 5 . As expected, the induction of SCI resulted in paralysis of the hind limbs, and the BBB scores showed a Table 1 ) confirmed that the combined treatment group showed significant differences in the mean ± SD number of myelinated axons and mitochondria in neurons compared with the other three groups (*P < 0.05 for D versus A, B and C) Methylprednisolone and Nogo A monoclonal antibody in spinal cord injury treated groups at week 4 were: MP, 11.9 ± 0.19; NEP1-40, 12.38 ± 0.21 and NEP1-40 plus MP, 13.98 ± 0.21 and were all significantly different compared with the trauma control group (P < 0.05).
Discussion
Spinal cord contusion injury is a standard model for investigating neuronal injury and regeneration. 20 This model was used to evaluate the effect of a combined therapy with acute intravenous MP and continuous NEP1-40 infusion on the initial inflammatory reaction, axonal remyelination and functional recovery following SCI. 21 The therapeutic potential of MP and NEP1-40 in treating spinal cord trauma was further explored in the present study, and a treatment regimen was defined that led to significant improvement in both the neurological outcome and histological markers of injury after compression of the spinal cord. Immunostaining revealed reduced numbers of ED1-positive cells infiltrating the site of contusion damage in the spinal cord of animals treated with MP plus NEP1-40. A concomitant increase in axonal remyelination and functional improvement were also observed in the combined treatment group compared with Transmission electron microscopy evaluation revealed better preservation and normal histological features in the combined treatment group. The present study, therefore, demonstrated that a combination of MP and NEP1-40 can influence both the secondary injuries as well as enhance axonal remyelination after SCI.
Spinal cord injury results in infiltration of macrophages and activation of the microglia at the injury site, 22 where these cells can clear debris from degenerating cells and myelin, but also secrete a number of proinflammatory cytokines. Although the beneficial effects of inflammation have been emphasized by some authors 23 and implantation of macrophages can promote axonal regeneration, 24 the general consensus is that functional outcome after SCI is improved by therapies that reduce inflammation. 25 ED-1 was chosen as a marker to identify infiltrating inflammatory cells in the present study. The number of ED1-positive cells counted in immunostained sections decreased significantly in rats treated with MP alone or in combination with NEP1-40. No significant difference in the number of ED1positive cells infiltrating the contusion site was found between the MP and combined treatment groups. In contrast, more ED1positive infiltrating inflammatory cells were seen at the site of injury in rats treated with NEP1-40 alone and those rats in the untreated trauma control group. This finding implies a relationship between MP administration and the anti-inflammatory reaction, indicating that MP has potent anti-inflammatory properties in a spinal cord contusion injury model, and is consistent with a previous report. 26 Adjuvant NEP1-40 infusion did not alter the effects of MP on the spinal cord, at least in terms of the most important antiinflammatory effects in the acute stage of SCI.
Treatment with MP alone had no direct pro-regenerative effects following SCI. It was shown that acute MP treatment did not increase neuronal and oligodendrocyte survival at 4 weeks. The multitude of factors affecting axonal regeneration dictate that combination strategies should be investigated as a means of significantly enhancing axonal regeneration after traumatic SCI. 27 The activity of NEP1-40 is based on its ability to antagonize the binding of myelin-associated inhibitors to NgR, thereby promoting axonal regeneration and functional recovery after SCI. 28 In the present study, it was shown that NEP1-40 treatment increased the overall neuronal survival at 4 weeks after compression injury. More NeuNpositive cells were observed in the spinal cords of rats treated with NEP1-40, which suggests that neurons were rescued. In addition to increased neuronal survival, NEP1-40 treatment was seen to improve oligodendrocyte survival.
These results indicate that MP and NEP1-40 are two neuroprotective agents that have independent actions, anti-inflammatory and pro-regenerative in nature, respectively. Compared with the other three treatment groups, combined treatment with MP and NEP1-40 significantly increased the numbers of neurons and oligodendrocytes at 4 weeks post-injury, which suggests an additive effect of administration of the two agents.
The ultrastructural findings suggested that MP, as well as NEP1-40, protected neurons, myelin, axons, and cytoplasmic organelles such as nuclei and mitochondria. The evaluation, based on a previously published grading system for quantitating ultrastructural findings, 18 showed the neuroprotective effects of MP, NEP1-40 and the combination of these two agents. When MP was compared with NEP1-40 at postinjury week 4, MP tended to have a greater • Received for publication 3 October 2009 • Accepted subject to revision 13 October 2009
• Revised accepted 4 March 2010 Copyright © 2010 Field House Publishing LLP protective effect on mitochondria, while NEP1-40 tended to be more effective in protecting axons and myelin, though neither of these effects reached statistical significance in this study. Combined treatment with both drugs, however, gave significantly better results than the use of either agent alone.
In addition to the histological studies, the effects of NEP1-40 and MP on behavioural recovery in the rats were observed. The effect of MP on functional recovery was apparent as early as the first day after SCI, whereas the effect of NEP1-40 was not manifest until 2 weeks after SCI. This observation indicated an early effect of MP and a much later onset of action of NEP1-40 treatment on behavioural recovery, consistent with their respective independent mechanisms of action. In the combined treatment group, functional recovery was more pronounced than with either MP or NEP1-40 treatment alone.
Taken together, combined treatment with NEP1-40 and MP tended to have a greater effect on functional and histological recovery than either treatment administered alone. These findings suggest an additive effect of administration of MP when combined with NEP1-40. It could be inferred, therefore, that MP acts to reduce secondary damage to the spinal cord by one or several reported mechanisms of action, 7 and that NEP1-40 increases the ability of axons to remodel and regenerate by blocking the effects of the inhibitory components of myelin. 29 The pharmacological effects of these reagents occurred in a temporally distinct manner.
In conclusion, the present study demonstrated that combination treatment with MP plus NEP1-40 not only attenuated haematogenous inflammatory cell infiltration but also enhanced neuronal and oligodendrocyte survival following SCI. The apparent different and complementary mechanisms of action of MP and NEP1-40 indicated that they were sequentially effective at limiting damage and promoting recovery. Future research should be directed toward evaluating the proper concentration and duration of NEP1-40 infusion in combination with MP on a large number of animals that have sustained SCI using other methods.
